Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

A re-engineered CAR T-cell receptor decreases risks of on-target off-tissue toxicity by enabling preferential recognition of EGFR on the basis of its overexpressed levels in cancer.